Popular antidepressant recalled over high levels of a cancer-causing compound

Breckenridge Pharmaceuticals has initiated a nationwide recall of specific lots of duloxetine, a generic version of the antidepressant Cymbalta, due to the presence of a nitrosamine impurity. Testing revealed levels of N-nitroso-duloxetine exceeding the Food and Drug Administration's (FDA) recommended limits, posing a potential long-term cancer risk to patients. This recall highlights ongoing regulatory scrutiny regarding manufacturing-related impurities in the pharmaceutical supply chain for widely used psychiatric and chronic pain medications.

The New Jersey-based drug manufacturer Breckenridge Pharmaceuticals is recalling several lots of duloxetine delayed-release capsules, which are commonly prescribed to treat depression, anxiety, and fibromyalgia. The recall was triggered after testing identified levels of N-nitroso-duloxetine above the acceptable threshold set by the U.S. Food and Drug Administration (FDA). Nitrosamines are chemical compounds that can inadvertently form during the manufacturing, storage, or packaging processes of certain medications, and long-term exposure to these impurities above recommended levels is associated with an increased risk of cancer.

The enforcement action covers specific lots distributed across the United States, including both 30mg and 60mg dosage strengths. According to the FDA enforcement report and the California Board of Pharmacy, the affected 30mg capsules carry the lot code 241180C with an expiration date of April 2027. For the 60mg capsules, two lots are involved: lot number 230286C, which expires in February 2026, and lot number 24072lC, which expires in February 2027.

Health officials and the FDA advise patients currently using the recalled medication to consult with their healthcare provider or pharmacist to determine the appropriate next steps. Crucially, the guidance emphasizes that patients should not discontinue their medication regimen without first speaking to a doctor, as medical supervision is necessary when transitioning from these treatments. The FDA defines such recalls as the removal of products that present a risk of injury, gross deception, or other defects, emphasizing the industry's responsibility to maintain safety standards during the production and distribution of prescription drugs.